Taegu
Taegu
Taegu, South Korea5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-10-05 | NCT04557462 | |
| A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura® | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Not stated | 2026-09-24 | NCT05217810 | |
| Asciminib RMP Study | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-04-20 | NCT05943522 | |
| Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea) | Primary Hypercholesterolemia or Mixed Dyslipidemia | Recruiting | Not stated | 2025-12-22 | NCT06770543 | |
| Regulatory Post-Marketing Surveillance Study for Brolucizumab | Neovascular Age-related Macular Degeneration | Recruiting | Not stated | 2025-01-14 | NCT04985487 |